Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck

World Journal of Clinical Oncology

Volumn 6, Issue 5, 2015, Pages 166-173

  Mix, Michael ^a   Singh, Anurag K ^a,c   Tills, Michael ^b   Dibaj, Shiva ^a   Groman, Adrienne ^a   Jaggernauth, Wainwright ^a   Rustum, Youcef ^a   Jameson, Michael B ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WAIKATO HOSPITAL   (New Zealand)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chemoprotective; Chemotherapy; Radiation therapy; Radioprotector; Selenium; Squamous cell cancer

Indexed keywords

EID: 84945121781     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i5.166     Document Type: Article

References (38)

1. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619 [PMID: 18235120 DOI: 10.1200/JCO.2007.14.1713]
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
3. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287 [PMID: 3365707]
4. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720 [PMID: 10793107]
5. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98 [PMID: 12506176]
6. Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M, Benhamou E. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006; 24: 2873-2878 [PMID: 16782926]
7. Platek ME, McCloskey SA, Cruz M, Burke MS, Reid ME, Wilding GE, Rigual NR, Popat SR, Loree TR, Gupta V, Warren GW, Sullivan M, Hicks WL, Singh AK. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 2013; 35: 684-688 [PMID: 22619040 DOI: 10.1002/hed.23024]
8. Rades D, Stoehr M, Kazic N, Hakim SG, Walz A, Schild SE, Dunst J. Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 1108-1114 [PMID: 17905528 DOI: 10.1016/j.ijrobp.20 07.07.2380]
9. Nangia S, Chufal KS, Tyagi A, Bhatnagar A, Mishra M, Ghosh D. Selective nodal irradiation for head and neck cancer using intensitymodulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice. Int J Radiat Oncol Biol Phys 2010; 76: 146-153 [PMID: 19553034 DOI: 10.1016/j.ijrobp.2009.01.060]
10. Altundag K, Silay YS, Altundag O, Yigitbasi OG, Gundeslioglu O, Gunduz M. Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. Med Hypotheses 2005; 64: 1162-1165 [PMID: 15823708 DOI: 10.1016/ j.mehy.2004.11.041]
11. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004; 10: 2561-2569 [PMID: 15073137 DOI: 10.1158/1078-0432. CCR-03-0268]
12. Cao S, Durrani FA, Tóth K, Rustum YM. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br J Cancer 2014; 110: 1733-1743 [PMID: 24619073 DOI: 10.1038/bjc.2014.85]
13. Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer 2012; 12: 293 [PMID: 22804960 DOI: 10.1186/1471-2407-12-293]
14. Fischer JL, Mihelc EM, Pollok KE, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 2007; 6: 355-361 [PMID: 17237294 DOI: 10.1158/1535-7163.MCT-06-0472]
15. Yang Y, Huang F, Ren Y, Xing L, Wu Y, Li Z, Pan H, Xu C. The anticancer effects of sodium selenite and selenomethionine on human colorectal carcinoma cell lines in nude mice. Oncol Res 2009; 18: 1-8 [PMID: 19911698 DOI: 10.3727/0965040097897456 47]
16. Stewart J, Ware J, Fortina P, Breaux J, Gulati S, Kennedy A. L-selenomethionine modulates high LET radiation-induced alterations of gene expression in cultured human thyroid cells. Oncol Rep 2006; 16: 569-574 [PMID: 16865257 DOI: 10.3892/ or.16.3.569]
17. Jeong SW, Jung HJ, Rahman MM, Hwang JN, Seo YR. Protective effects of selenomethionine against ionizing radiation under the modulation of p53 tumor suppressor. J Med Food 2009; 12: 389-393 [PMID: 19459742 DOI: 10.1089/jmf.2007.0719]
18. Fischer JL, Lancia JK, Mathur A, Smith ML. Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex. Anticancer Res 2006; 26: 899-904 [PMID: 16619485]
19. Li L, Xie Y, El-Sayed WM, Szakacs JG, Franklin MR, Roberts JC. Chemopreventive activity of selenocysteine prodrugs against tobacco-derived nitrosamine (NNK) induced lung tumors in the A/J mouse. J Biochem Mol Toxicol 2005; 19: 396-405 [PMID: 16421895 DOI: 10.1002/jbt.20105]
20. Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res 2006; 12: 1237-1244 [PMID: 16489079 DOI: 10.1158/1078-0432.CCR-05-2004]
21. Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol 2008; 62: 499-508 [PMID: 17989978 DOI: 10.1007/s00280-007-0631-4]
22. Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 2005; 5: 132-135 [PMID: 16098255 DOI: 10.3816/CCC.2005.n.026]
23. International Commissino on Radiation Units and Measurements. ICRU report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda, MD, 1993
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216 [PMID: 10655437 DOI: 10.1093/ jnci/92.3.205]
25. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004; 190: 666-674 [PMID: 15272392 DOI: 10.1086/422603]
26. Eroglu C, Unal D, Cetin A, Orhan O, Sivgin S, Oztürk A. Effect of serum selenium levels on radiotherapy-related toxicity in patients undergoing radiotherapy for head and neck cancer. Anticancer Res 2012; 32: 3587-3590 [PMID: 22843950]
27. Büntzel J, Riesenbeck D, Glatzel M, Berndt-Skorka R, Riedel T, Mücke R, Kisters K, Schönekaes KG, Schäfer U, Bruns F, Micke O. Limited effects of selenium substitution in the prevention of radiation-associated toxicities. results of a randomized study in head and neck cancer patients. Anticancer Res 2010; 30: 1829-1832 [PMID: 20592387]
28. Muecke R, Schomburg L, Glatzel M, Berndt-Skorka R, Baaske D, Reichl B, Buentzel J, Kundt G, Prott FJ, Devries A, Stoll G, Kisters K, Bruns F, Schaefer U, Willich N, Micke O. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010; 78: 828-835 [PMID: 20133068 DOI: 10.1016/j.ijrobp.2009.08.013]
29. Jahangard-Rafsanjani Z, Gholami K, Hadjibabaie M, Shamshiri AR, Alimoghadam K, Sarayani A, Mojtahedzadeh M, Ostadali- Dehaghi M, Ghavamzadeh A. The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial. Bone Marrow Transplant 2013; 48: 832-836 [PMID: 23292233 DOI: 10.1038/bmt.2012.250]
30. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non- Hodgkin's lymphoma. Biol Trace Elem Res 2009; 127: 200-210 [PMID: 18953506 DOI: 10.1007/s12011-008-8240-6]
31. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El- Desoky H, Saleh R, Moussa MA. The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lym phoma patients: correlation with response and survival. Biol Trace Elem Res 2007; 120: 1-10 [PMID: 17916949 DOI: 10.1007/ s12011-007-0029-5]
32. Rajan S, Jameson M, de Groot C, Gomez J, Tills M, Dibaj S, Tan W, Ramnath N, Rustum Y, Singh AK. Concurrent Carboplatin, Paclitaxel, and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase 2 Multicenter Trial. Int J Radiat Oncol 2013; 87: S76-S77 [DOI: 10.1016/j.ijrobp.2013.06.198]
33. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 2010; 3: 1035-1043 [PMID: 20647337 DOI: 10.1158/1940-6207.CAPR-09-0143]
34. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 2013; 73: 328-335 [PMID: 22887343 DOI: 10.1002/pros.22573]
35. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 2011; 4: 1761-1769 [PMID: 21896650 DOI: 10.1158/1940-6207.CAPR-10-0343]
36. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556 [PMID: 21990298 DOI: 10.1001/jama.2011.1437]
37. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003; 95: 1477-1481 [PMID: 14519754 DOI: 10.1093/jnci/ djg061]
38. Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 2011; 4: 1938-1944 [PMID: 21846796 DOI: 10.1158/1940-6207.CAPR-10-0259]